Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

TRAILBLAZER-ALZ 6 updates support new donanemab dosing schedule for AD
10 Oct 2025
bởiAudrey Abella
In the 18-month results from the phase IIIb TRAILBLAZER-ALZ 6 trial, the newly recommended dosing schedule of donanemab results in a significant reduction in the incidence of amyloid-related imaging abnormalities with effusion/oedema (ARIA-E) compared with standard dosing in adults with early symptomatic Alzheimer’s disease (AD).
10 Oct 2025

Tirzepatide proves safety, efficacy in T1D in real world
09 Oct 2025
bởiStephen Padilla
The use of tirzepatide in a real-world setting demonstrates a favourable safety profile and results in weight loss, lower insulin requirements, and better glycaemic measurements among patients with type 1 diabetes (T1D), as shown in a study presented at EASD 2025.
09 Oct 2025







